Rocket begins patient dosing in phase 1 trial of RP-A501 in Danon disease
University of California San Diego (UCSD) Health is the initial and lead center for the Phase 1 clinical trial under the leadership of Eric Adler, M.D., Director of
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).
Sustained efficacy of ULTOMIRIS was observed on the co-primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase (LDH) levels and the secondary endpoints of LDH level reduction
Under the agreement, Dr. Reddy’s will receive U.S.$70 million as upfront consideration, U.S.$40.5 million in near term milestones and additional financial considerations including existing contractual obligation and inventory.